Stockscreener 앱 받기
12.93
2.54%
0.32
시간 외 거래:
12.92
-0.010
-0.08%
전일 마감가:
$12.61
열려 있는:
$12.73
하루 거래량:
2.46M
Relative Volume:
1.14
시가총액:
$965.21M
수익:
$65,400
순이익/손실:
$-46.34M
주가수익비율:
-14.05
EPS:
-0.92
순현금흐름:
$-38.74M
1주 성능:
+25.17%
1개월 성능:
+13.72%
6개월 성능:
+23.38%
1년 성능:
+169.66%
1일 변동 폭
$12.50
$12.97
1주일 범위
$9.935
$12.97
52주 변동 폭
$4.67
$17.43
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.93 | 941.32M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
Why CorMedix Inc. stock attracts strong analyst attentionWeekly Risk Report & Capital Efficiency Focused Ideas - thegnnews.com
Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT - msn.com
CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention - msn.com
CorMedix Inc. Advances in Infection Prevention with DEFENCATH® Study - TipRanks
Why CorMedix (CRMD) Might be Well Poised for a Surge - sharewise.com
Cormedix Inc. Advances Pediatric Study on DefenCath® for Infection Prevention - TipRanks
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position - simplywall.st
CorMedix (CRMD.O) Surges 8% — Is It a Technical Trigger or a Broader Sector Play? - AInvest
CorMedix Raises $150M in Convertible Notes Offering - AInvest
Undervalued Healthcare Stocks to Buy: Eli Lilly, CorMedix, and Johnson & Johnson - AInvest
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? - ca.finance.yahoo.com
Will CorMedix Inc. benefit from AI trendsJuly 2025 Chart Watch & Daily Technical Forecast Reports - mustnews.co.kr
Momentum Screeners Rank CorMedix Inc. in Top 5 TodayAI Screening for Swing Trade Picks Finds Momentum - sundaytimes.kr
CorMedix Inc. Just Beat EPS By 50%: Here's What Analysts Think Will Happen Next - 富途牛牛
CorMedix Completes $150M Convertible Notes Offering - TipRanks
CorMedix completes $150 million convertible notes offering on Nasdaq By Investing.com - Investing.com Nigeria
CorMedix completes $150 million convertible notes offering on Nasdaq - Investing.com
Unpacking CorMedix’s 14.2% Intraday Surge: What’s Driving the Move? - AInvest
CorMedix (CRMD.O) Surges 9.7% Intraday—No Fundamentals, So What's Driving It? - AInvest
CorMedix’s SWOT analysis: acquisition boosts biopharmaceutical stock’s outlook By Investing.com - Investing.com Nigeria
CorMedix’s SWOT analysis: acquisition boosts biopharmaceutical stock’s outlook - Investing.com
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - Zacks Investment Research
CorMedix Inc. (NASDAQ:CRMD) Q2 2025 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Earnings Call Highlights Strategic Growth - TipRanks
Both Individual Investors Who Control a Good Portion of CorMedix Inc. (NASDAQ:CRMD) Along With Institutions Must Be Dismayed After Last Week's 16% Decrease - 富途牛牛
CorMedix Inc. stock trend outlook and recovery pathShort Squeeze Opportunities with Indicators - Newser
Is CorMedix Inc. part of any ETFShort-Term Gainers List - thegnnews.com
CorMedix Inc. stock trend forecastFree Real-Time Analysis With Entry Targets - Newser
Strategic Value and Growth Potential of CorMedix Post-Melinta Acquisition - AInvest
Short Interest Drops in CorMedix Inc. After RallyReal-Time Analysis With Entry Targets In Progress - beatles.ru
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - Stocktwits
CorMedix Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - MSN
Cormedix Inc Reports Q2 2025 Earnings: $39.7M in Revenue, $0.29 EPS, and Acquisition of Melinta Therapeutics - AInvest
Applying big data sentiment scoring on CorMedix Inc.Free Consistent Income Focused Trade List - Newser
Press Release: Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
HC Wainwright Maintains Buy Rating on Cormedix, Adjusts Price Target to $17.00 - AInvest
Unraveling the Drop in CorMedix (CRMD.O): A Technical and Market Flow Deep Dive - AInvest
Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ... By GuruFocus - Investing.com Canada
CorMedix signs agreement to acquire Melinta for $300m - Yahoo Finance
CorMedix: Q2 Earnings Snapshot - Greenwich Time
CorMedix Inc. Reports Strong Q2 2025 Results - TipRanks
Transcript : CorMedix Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Cormedix’s Strategic Growth Potential Boosted by Melinta Therapeutics Acquisition - TipRanks
CorMedix (CRMD.O) Suffers Sharp Intraday Drop: What’s the Story Behind? - AInvest
CRMD Faces Major Legal Battle - StocksToTrade
CorMedix Surpasses Expectations with Q2 Earnings Surge - AInvest
CorMedix Forecasts FY25 Pro Forma Revenue of $305M-$335M - AInvest
M&A News: CorMedix Stock (CRMD) Plunges 11% Despite $300M Melinta Deal - TipRanks
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):